Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jennifer Rothschild

Urology Sacramento, CA Medical Doctor

NPI 1225142490 CMS profile 1166857

4860 Y Street, Ste 3500, Uc Davis Medical Center Department Of Urology, Sacramento, CA 95817

Open in the dashboard

General payments

$2,214

56 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,589 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Jennifer Rothschild of Sacramento, CA is reported in the CMS Open Payments database as having received $2,214 across 56 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,589 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 46th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $896 11
2023 General $820 11
2022 General $143 13
2021 General $151 17
2020 General $181 2
2019 General $23 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Rothschild
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Jennifer Rothschild were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Jennifer Rothschild Urology median Middle half National median
2019 $23 $480 $147–$1,201 $163
2020 $181 $246 $87–$645 $114
2021 $151 $358 $111–$1,000 $132
2022 $143 $476 $143–$1,263 $149
2023 $820 $560 $168–$1,461 $160
2024 $896 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Axonics Modulation Technologies, Inc. $1,408 15 payments
  2. Rochester Medical Corporation $264 29 payments
  3. Boston Scientific Corporation $190 2 payments
  4. Medtronic, Inc. $181 1 payment
  5. AbbVie, Inc. $61 2 payments
  6. C. R. Bard, Inc. & Subsidiaries $56 4 payments
  7. Allergan Inc. $23 1 payment
  8. Cook Medical LLC $21 1 payment
  9. C. R. Bard Foundation, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,530 51 payments
  2. Travel and Lodging $684 5 payments
Products named General payments · program years 2019–2024
  1. Axonics $1,213 13 payments
  2. Bulkamid $837 7 payments
  3. INTERSTIM $181 1 payment
  4. Axonics r-SNM System $167 1 payment
  5. Solyx SIS System $165 1 payment
  6. Bard Urinary Drainage Bag $44 3 payments
  7. BOTOX Urology $33 1 payment
  8. BOTOX Botox Therapeutic $27 1 payment
  9. AMS 700 $26 1 payment
  10. BOTOX Hyperhydrosis $23 1 payment
  11. Other $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,112

Median for Urology: 1,053

Drug cost

$321,523

Median for Urology: $101,464

Branded share of claims

59.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 277 $184,561
Myrbetriq Mirabegron Brand 155 $114,599
Estradiol Generic 103 $6,931
Oxybutynin Chloride Er Oxybutynin Chloride Brand 73 $3,036
Solifenacin Succinate Generic 65 $2,633
Tolterodine Tartrate Er Tolterodine Tartrate Brand 41 $2,510
Tamsulosin Hcl Generic 125 $1,835
Trospium Chloride Generic 27 $1,393
Methenamine Hippurate Generic 23 $1,179
Darifenacin Er Darifenacin Hydrobromide Brand 14 $932

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$123,588

Medicare's payments for the services billed

Medicare patients

614

Average age 69

Services billed

2,719

326 women, 288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Diabetes 32%
Depression 32%
Chronic kidney disease 29%
Ischemic heart disease 24%
Cancer 22%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record